Germany
Japan
United Kingdom
China
Research Areas
Download
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E4
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 428.00
In Stock
USD 440.00
2 Weeks
USD 515.00
In Stock
USD 310.00
2 Weeks
HLA Class I ABC mouse monoclonal antibody, clone LY5.1, Purified
| Applications | IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
IL10 rat monoclonal antibody, clone 12G8
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 440.00
2 Weeks
Rat Anti-Human/Mouse CD45R (B220) Purified (100 ug)
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
TNF alpha (TNF) mouse monoclonal antibody, clone 2C8
| Applications | ELISA, FN, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
IL6 mouse monoclonal antibody, clone 5G8, Purified
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
IL6 mouse monoclonal antibody, clone 1B6, Purified
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
IL6 mouse monoclonal antibody, clone 1E3, Purified
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
TNF alpha (TNF) mouse monoclonal antibody, clone CH8820, Aff - Purified
| Applications | ELISA, FN, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Anti-Human CD45RA Purified (100 ug)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal ITGB3 (CD61) Antibody
| Applications | IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Active filters
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Filter by
Target Symbol
- IL6 (119)
- IL1RL1 (102)
- CD4 (85)
- PECAM1 (73)
- PDCD1 (70)
- PTPRC (58)
- CD99 (57)
- LGALS3 (54)
- CD68 (50)
- CD5 (48)
- CD19 (43)
- NCAM1 (43)
- CD274 (42)
- KIT (42)
- MS4A1 (42)
- TNFRSF8 (39)
- CD34 (30)
- CD2 (27)
- CR2 (27)
- MME (27)
- WNT3 (27)
- ESR1 (25)
- FCER2 (25)
- CD22 (23)
- CD33 (23)
- DVL2 (22)
- IL1RN (22)
- CRP (21)
- IL2RA (20)
- TNF (20)
- ANAPC11 (19)
- IL3RA (19)
- ROR2 (19)
- TYRO3 (19)
- ANAPC2 (18)
- CD14 (18)
- CD79B (18)
- MAPK8 (18)
- CSF3 (17)
- MAPK9 (16)
- CD3E (15)
- ANPEP (14)
- CD8A (14)
- CD74 (12)
- FCGR1A (12)
- MAPK10 (9)
- POSTN (9)
- PTK7 (9)
- RORA (9)
- IL2 (8)
- IL6R (8)
- ITGA2B (8)
- ITGB3 (8)
- AGTPBP1 (7)
- CD7 (7)
- CD79A (7)
- CD1A (6)
- IL1A (6)
- IL36G (6)
- ROR1 (6)
- CALR (5)
- IL12B (5)
- IL18 (5)
- TLR8 (5)
- TOLLIP (5)
- ESR2 (4)
- FCGR3A (4)
- HLA-A (4)
- IL1B (4)
- IL36A (4)
- CRYGD (3)
- HLA-DRB5 (3)
- IL10 (3)
- ITGAX (3)
- LEF1 (3)
- WNT3A (3)
- CXCL8 (2)
- FUT4 (2)
- HLA CLASS II (2)
- HLA-DQA2 (2)
- IL6RA (2)
- TLR2 (2)
- TLR3 (2)
- TMED1 (2)
- WNT5B (2)
- ANAPC5 (1)
- ARAF (1)
- BRAF (1)
- CASP1 (1)
- CD10 (1)
- CD207 (1)
- CD30 (1)
- CD3D (1)
- CD3G (1)
- CDC42SE2 (1)
- CKMT2 (1)
- ELK3 (1)
- IL1R2 (1)
- IRS1 (1)
- MAP2K2 (1)
Reactivities
Applications
Antibody Hosts
Isotypes
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (11)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (6)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
Assay Types
Families
- Druggable Genome (1479)
- Transmembrane (1147)
- ES Cell Differentiation/IPS (486)
- Secreted Protein (455)
- Adult stem cells (175)
- Protein Kinase (150)
- Embryonic stem cells (86)
- Stem cell - Pluripotency (75)
- Induced pluripotent stem cells (73)
- Transcription Factors (57)
- Phosphatase (56)
- Protease (43)
- Nuclear Hormone Receptor (36)
- Cancer stem cells (31)
- Stem cell relevant signaling - Wnt Signaling pathway (4)
- Stem cell relevant signaling - JAK/STAT signaling pathway (1)
Pathways
- Hematopoietic cell lineage (652)
- Cell adhesion molecules (CAMs) (494)
- Cytokine-cytokine receptor interaction (272)
- Pathways in cancer (261)
- T cell receptor signaling pathway (254)
- Toll-like receptor signaling pathway (217)
- Primary immunodeficiency (188)
- NOD-like receptor signaling pathway (176)
- Jak-STAT signaling pathway (175)
- Prion diseases (167)
- Graft-versus-host disease (151)
- Hypertrophic cardiomyopathy (HCM) (135)
- Leukocyte transendothelial migration (131)
- Cytosolic DNA-sensing pathway (122)
- B cell receptor signaling pathway (109)
- Antigen processing and presentation (100)
- Melanogenesis (98)
- Wnt signaling pathway (98)
- MAPK signaling pathway (87)
- Progesterone-mediated oocyte maturation (83)
- Fc gamma R-mediated phagocytosis (71)
- Colorectal cancer (67)
- RIG-I-like receptor signaling pathway (61)
- Basal cell carcinoma (56)
- Endocytosis (56)
- Fc epsilon RI signaling pathway (56)
- Adipocytokine signaling pathway (54)
- Focal adhesion (54)
- Type II diabetes mellitus (54)
- Acute myeloid leukemia (49)
- ErbB signaling pathway (49)
- Lysosome (49)
- Neurotrophin signaling pathway (47)
- Insulin signaling pathway (46)
- Epithelial cell signaling in Helicobacter pylori infection (45)
- GnRH signaling pathway (44)
- Pancreatic cancer (44)
- Type I diabetes mellitus (40)
- Oocyte meiosis (39)
- Cell cycle (38)
- Ubiquitin mediated proteolysis (38)
- Alzheimer's disease (37)
- Apoptosis (35)
- Renin-angiotensin system (35)
- Regulation of actin cytoskeleton (34)
- Hedgehog signaling pathway (32)
- Allograft rejection (31)
- Systemic lupus erythematosus (30)
- Complement and coagulation cascades (26)
- Natural killer cell mediated cytotoxicity (22)
- Pathogenic Escherichia coli infection (22)
- Notch signaling pathway (21)
- Dilated cardiomyopathy (19)
- Asthma (17)
- Autoimmune thyroid disease (15)
- Metabolic pathways (14)
- Amyotrophic lateral sclerosis (ALS) (13)
- Glutathione metabolism (13)
- TGF-beta signaling pathway (12)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (11)
- Viral myocarditis (9)
- Chemokine signaling pathway (8)
- ECM-receptor interaction (7)
- Endometrial cancer (7)
- Prostate cancer (7)
- Adherens junction (6)
- Bladder cancer (5)
- Chronic myeloid leukemia (5)
- Glioma (5)
- Renal cell carcinoma (5)
- Thyroid cancer (5)
- VEGF signaling pathway (5)
- Vascular smooth muscle contraction (5)
- Long-term potentiation (4)
- Melanoma (4)
- Non-small cell lung cancer (4)
- mTOR signaling pathway (4)
- Axon guidance (3)
- Long-term depression (3)
- Tight junction (3)
- Gap junction (2)
- Small cell lung cancer (2)
- Arginine and proline metabolism (1)
- Inositol phosphate metabolism (1)
- Phosphatidylinositol signaling system (1)
- Vibrio cholerae infection (1)